(Nasdaq: QNTM) Has 5 Potential Breakout Catalysts (Low Float And Key Analyst Target To Consider)

Got a moment? Let's take a stroll down memory lane.

*Sponsored by Quantum BioPharma Ltd. StockWireNews (Nasdaq: QNTM) Has 5 Potential Breakout Catalysts (Low Float And Key Analyst Target To Consider) October 23rd Greetings Readers, Got a moment? Let's take a stroll down memory lane. The last 4 weeks have been filled with breakout ideas that have popped off for strong intraday and short term moves. Soak these in (all runs are approximate %): 9/30's Profile - Blasted 32% intraday. 10/2's Profile - Ran 16% intraday and 27% within 3 weeks. 10/4's Profile - Surged 29% intraday and 157% in roughly 10 days. 10/10's Profile - Ripped 84% intraday. 10/14's Profile - Popped 21% intraday. Good stuff, but there could be breakout buzz circling a different low float Nasdaq idea right this moment. Clocking in with just over 1Mn shares in its float, this Nasdaq Biopharma could be on the verge of making a statement if the right type of catalyst comes along. With the company looking to take on multiple markets including a $7.7Bn market that is ripe for disruption, Wall Street's attention may come on like wildfire. And as huge news of a pending U.S. federal lawsuit being filed seeking over $700Mn in damages, now could be the perfect time to consider this company for your watch-list: *Quantum BioPharma Ltd. (Nasdaq: QNTM)* Quantum BioPharma (formerly known as FSD Pharma Inc.) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. And right now, QNTM has several potential catalysts capable of creating breakout buzz. Take a look: #1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility. #2. An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels. #3. unbuzzd™ To Find New Home In Markets Throughout Puerto Rico, Latin America, and South America With Master Distribution Agreement. #4. A Game-Changing Launch On Amazon Puts unbuzzd™ On The Map. (Momentum Building?!?) #5. A Key Agreement Entered - Clinical Study To Observe And Quantify Disease Progression In MS Patients. But more on those in a second... UNBUZZD™ - Mental Alertness & Detoxification when Alcohol is Consumed What is UNBUZZD™ in a Nutshell? UNBUZZD™ is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. Small focus group research indicates UNBUZZD™ reduces BrAC faster than what the body would do naturally. Clinical trials are being planned for further validation. The active ingredients in UNBUZZD™'s formula help restore mental alertness post-alcohol consumption in an average of about 15-30 minutes. Greater Purpose Today's recovery drinks have one goal: to relieve undeniable discomfort after a night out of drinking, infamously known as the "hangover." UNBUZZD™ is more than a hangover cure product. The company's purpose is to re-shape the paradigm by taking an innovative approach to reduce the burden of the aftermath effects of excess alcohol consumption on society. In short, they understand that one person's inebriation can impact countless others. UNBUZZD™ turns the time in your favor. Their formulation was curated through scientific research to expedite recovery from inebriation and to accelerate ethanol metabolism in your body, potentially eliminating any performance concerns today or tomorrow. Quantum BioPharma has licensed UNBUZZD™ to Celly Nutrition Corp. ("Celly Nu") and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. Two distinct markets can be served with this technology: 1. Consumer Market (UNBUZZD™) – enjoy alcohol responsibly, work-to-life balance. 2. Hospital Market (REKVRY™) – help an unmet need in the ER and other healthcare settings, reducing costs and burden on healthcare resources/staff. Market Opp. There has yet to be a product backed by strong clinical data that targets reducing BAC (BrAC) levels and Mental Alertness, directly and efficiently. UNBUZZD™ is MORE THAN Hangover Cure Products. Global Hangover Cure Products market size was valued at $2.2Bn in 2023 and expected to reach $7.7Bn by 2032 (Straits Research):

LUCID-MS: Patented new chemical entity (NCE) Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models. LUCID-MS: Disease Modifying Enabling Remyelination A sampling of the novel qualities of Lucid-MS include: Excellent efficacy in various preclinical animal models Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation Does not suppress immune system (non-immunomodulatory) Potential oral administration with easy dosing regimen Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS. Today there is no cure for Multiple Sclerosis. Quantum BioPharma ("QNTM") is trying to change this for millions of people. Read more here from the company's website. ----- (Nasdaq: QNTM): 5 Potential Breakout Catalysts To Focus On Immediately #1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility. According to the Yahoo Finance website, QNTM has a very small float. In fact, the website reports this profile to have approximately 1.07Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive company news in the second half of 2024 provide breakout buzz? ----- #2. An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels. Back in August, BJ Cook, an analyst with Singular Research, updated a price target for QNTM to $12.80. From Tuesday's closing valuation, that target provides QNTM with a potential upside of over 100%! Here are a few highlights from the report: The successful launch of unbuzzdTM on Amazon, marks a significant milestone for the firm. Furthermore, ethics approval in Australia for Phase-1 multiple ascending dose study for Lucid-MS signifies a crucial step in the progress towards development of a novel treatment for multiple sclerosis. We reiterate our Buy-Venture rating and adjust our target price to $12.80 per share. ----- #3. unbuzzd™ To Find New Home In Markets Throughout Puerto Rico, Latin America, and South America With Master Distribution Agreement. Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America Toronto, Ontario--(Newsfile Corp. - October 7, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma") provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu" or the "Company"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness. On October 7, 2024, Celly Nu announced signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America as follows: Vancouver, BC - October 7, 2024 - Celly Nutrition Corp. ("Celly Nu" or the "Company"), led by CEO John Duffy, formerly Vice-President of National Sales of Coca-Cola, and co-chaired by Gerry David, former CEO of Celsius Holdings, has secured a master distribution agreement with FUSION Consulting Group ("Fusion"). Based in Puerto Rico, FUSION is a leading brand incubator and distributor of health-conscious food and beverages across Puerto Rico, the Caribbean, and parts of Central and South America. This partnership will bring unbuzzd™, Celly Nu's innovative alcohol metabolism supplement, to new markets through FUSION's robust distribution network. unbuzzd's Ready-to-Mix (RTM) powder sticks are available now on Amazon in 3-packs and 18 packs, with Ready-to-Drink (RTD) 12oz cans coming soon. FUSION will handle distribution for both formats, alongside its impressive portfolio that includes CELSIUS, SHINE Water, Tona Cerveza, and Kin Whiskey. John Duffy, CEO of Celly Nutrition Corp. stated, "Our partnership with FUSION marks a pivotal moment for unbuzzd. Their proven success in growing brands across the region will help us expand our footprint while delivering a functional, science-backed product. Eduardo Santacana and his team at FUSION are the perfect partners to help us introduce unbuzzd to consumers who seek a better way to enjoy alcohol responsibly." Eduardo Santacana, CEO of FUSION Consulting Group, added: "It's an exciting opp. to be part of unbuzzd's journey. This innovative product helps metabolize alcohol faster, promoting clarity and minimizing the aftereffects of drinking. We're eager to help bring unbuzzd's unique benefits to consumers across the Caribbean and beyond." As unbuzzd™ enters key vacation destinations, where alcohol consumption is often part of the experience, the partnership with FUSION opens doors to major retail customers including Walmart, Walgreens, CVS, Costco, Sams, Farmacias Caridad, Pueblo Supermarkets, Supermax and many more. Read the full article here. ----- #4. A Game-Changing Launch On Amazon Puts unbuzzd™ On The Map. (Momentum Building?!?) Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon... TORONTO, ON / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), ..., today announces that highly-anticipated launch of unbuzzd™, a groundbreaking product designed to help individuals recover from the adverse effects of alcohol consumption and prepare for what's next. unbuzzd™ Clear Eyed Citrus Powder Sticks are now available on Amazon(dot)com. ... Celly Nutrition's leadership team brings unparalleled experience and expertise to the table. The company is led by CEO John Duffy, a seasoned executive with a distinguished career at Coca-Cola Enterprises and The Coca-Cola Company. Duffy's vision is further complemented by the strategic guidance of beverage industry luminary and Celly Nu Board Co-Chair Gerry David, the former CEO of Celsius Holdings, Inc., who played a pivotal role in establishing Celsius as a leading name in the beverage industry. "Having been a part of many game-changing products including Celsius, I believe unbuzzd is the next big innovation in the consumer products space," said David. ... Read the full article here. ----- #5. A Key Agreement Entered - Clinical Study To Observe And Quantify Disease Progression In MS Patients. Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ..., today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS). "We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. Read the full article here. ----- QNTM Recap - 5 Potential Breakout Catalysts To Consider #1. A Minuscule Float Could Provide Strong Potential For Explosive Volatility. #2. An Analyst Target Suggests (Nasdaq: QNTM) May Be Undervalued From Current Levels. #3. unbuzzd™ To Find New Home In Markets Throughout Puerto Rico, Latin America, and South America With Master Distribution Agreement. #4. A Game-Changing Launch On Amazon Puts unbuzzd™ On The Map. (Momentum Building?!?) #5. A Key Agreement Entered - Clinical Study To Observe And Quantify Disease Progression In MS Patients. ----- Coverage is officially initiated on (Nasdaq: QNTM). Consider it for your watch-list this week. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and StockWireNews ("SWN") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. The single member of SWN Media LLC owns and operates smallcapfirm . com ("SCF"), owns and operates fierceinvestor . com ("FI"), and owns and operates stockstreetwire . com ("SSW"). From time to time, StockWireNews, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: www.stockwirenews.net/disclosure Quantum BioPharma Ltd. (QNTM:US) previously changed their company name and ticker symbol from FSD Pharma Inc. (HUGE:US). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC was hired for a period beginning on 4/21/24 and ending on 4/22/24 to publicly disseminate information about (HUGE:US) via digital communications. Under this agreement, we were paid twenty thousand USD ("Funds"). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC was hired for a period beginning on 8/8/24 and ending on 8/9/24 to publicly disseminate information about (HUGE:US) via digital communications. Under this agreement, we were paid seventeen thousand five hundred USD ("Funds"). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC was hired for a period beginning on 8/29/24 and ending on 8/30/24 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, we were paid seventeen thousand five hundred USD ("Funds"). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired by TD Media LLC for a period beginning on 10/22/2024 and ending on 10/23/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, SWN Media was paid seventeen thousand five hundred USD ("Funds"). Neither SWN Media LLC or its member owns shares of (QNTM:US). The single member of SWN Media LLC is also the single member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Quantum BioPharma Ltd., TD Media LLC has been hired for a period beginning on 10/21/2024 and ending on 10/31/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, we have been paid sixty-five thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer. To date, TD Media LLC has been paid two hundred ninety-five thousand USD ("Funds") to publicly disseminate information about (QNTM:US) via digital communications. Neither TD Media LLC or its member owns shares of (QNTM:US). https://lifewatermedia.com/qntm-disclosure-v2/ Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States